8 completed, 1 active not recruiting, 1 recruiting. 10 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 8, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow pasireotide: new trials by email Literature Review of pasireotide trials Research Report on pasireotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET [177Lu]Lu-DOTA-TATE, Octreotide LAR - Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 240 | 2025-05-30 | 2026-09-11 |
| Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution - Gastro-enteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | Advanced Accelerator Applications | 226 | 2020-01-08 | 2026-01-21 |
| Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Pasireotide LAR - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 123 | 2015-03-31 | 2019-12-10 |
| Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg - Cushing's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 150 | 2011-11-04 | 2018-05-22 |
| Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 198 | 2010-07-19 | 2018-04-05 |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Pasireotide, cabergoline - Non-functioning Pituitary Adenomas, Prolactinomas | Phase 2 / Phase 3 | Completed | Universidade Federal do Rio de Janeiro | 21 | 2010-03-01 | 2016-08-22 |
| Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess Pasireotide (SOM230), placebo - Pancreatic Cancer | Phase 3 | Completed | Memorial Sloan Kettering Cancer Center | 439 | 2009-10-01 | 2016-02-01 |
| Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease Pasireotide, Octreotide - Symptomatic Refractory Resistant Carcinoid Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 186 | 2008-04-01 | 2013-07-30 |
| Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Pasireotide, Octreotide - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 358 | 2008-02-11 | 2017-07-02 |
| Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Pasireotide - Cushing's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 162 | 2006-12-01 | 2016-03-08 |
Acromegaly (3) · Gastro-enteropancreatic neuroendocrine tumor (2) · Pituitary ACTH Hypersecretion (2) · Pituitary Neoplasms (2) · Carcinoid Tumor (1) · Gigantism (1) · Growth Disorders (1) · Hyperpituitarism (1) · Lymphoma, Follicular (1) · Pancreatic Neoplasms (1) · Prolactinoma (1)
Novartis Pharmaceuticals (7) · Advanced Accelerator Applications (1) · Memorial Sloan Kettering Cancer Center (1) · Universidade Federal do Rio de Janeiro (1)
France (8) · Italy (8) · United States (8) · Brazil (7) · Canada (7) · Germany (7) · Spain (7) · United Kingdom (7) · Argentina (6) · Belgium (6) · Poland (6) · China (5) · Israel (5) · Turkey (Türkiye) (5) · Netherlands (4)
Peter Allen, MD (1)
PMID 22397653, PMID 23746264, PMID 24287689, PMID 24849084, PMID 25103549, PMID 25260838, PMID 25537481, PMID 26437217, PMID 27039081, PMID 27405306, PMID 28289402, PMID 29032078, PMID 31465533, PMID 31804965, PMID 31875276, PMID 32117045, PMID 32217809, PMID 32385851, PMID 33973550, PMID 38851203, PMID 39570708, PMID 40473457, PMID 42604001
2009 (1), 2014 (1), 2023 (1)